Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | CPT2 | P23786 | 1/20 | 0.36 |
| ▸ | CPT1A | P50416 | 1/20 | 0.36 |
| ▸ | ACE | P12821 | 8/20 | 0.36 |
| ▸ | REN | P00797 | 4/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | F2 | P00734 | 1/20 | 0.36 |
| ▸ | LTA4H | P09960 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | PEPD | P12955 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.36 |
| ▸ | HTR2A | P28223 | 1/20 | 0.36 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.36 |
| ▸ | HRH1 | P35367 | 1/20 | 0.36 |
| ▸ | THPO | P40225 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6210297 | 1.00 | RAB9A (0.38) | RAB9APOLBCPT2CPT1AACE | |
| SCHEMBL2672951 | 1.00 | RAB9A (0.38) | RAB9APOLBCPT2CPT1AACE | |
| SCHEMBL3089785 | 0.95 | CPT2 (0.40) | RAB9APOLBCPT2CPT1ASMN1; SMN2 | |
| SCHEMBL3257721 | 0.95 | CPT2 (0.40) | RAB9APOLBCPT2CPT1ASMN1; SMN2 | |
| SCHEMBL17941198 | 0.95 | CPT2 (0.40) | RAB9APOLBCPT2CPT1ASMN1; SMN2 | |
| SCHEMBL25177048 | 0.90 | — | — | |
| SCHEMBL2097443 | 0.90 | — | — | |
| SCHEMBL1905642 | 0.90 | — | — | |
| SCHEMBL17309478 | 0.87 | CHRM2 (0.37) | RAB9APOLBCCR1 | |
| SCHEMBL19065845 | 0.87 | CHRM2 (0.37) | RAB9APOLBCCR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4397309-A2 | BICYCLIC KETONE COMPOUNDS AND METHODS OF USE THEREOF | F. Hoffmann-La Roche AG (CH) | 2024-07-10 | — | — | EP | disclosed |
| EP-4322945-A2 | KRAS G12C INHIBITORS | Mirati Therapeutics, Inc. (US) | 2024-02-21 | — | — | EP | disclosed |
| EP-3652178-B1 | BICYCLIC KETONE COMPOUNDS AND METHODS OF USE THEREOF | HOFFMANN LA ROCHE (CH) | 2024-01-24 | — | — | EP | disclosed |
| US-11834461-B2 | Bicyclic ketone compounds and methods of use thereof | GENENTECH, INC. (US) | 2023-12-05 | — | — | US | disclosed |
| EP-4087573-A1 | KRAS G12C INHIBITORS | Mirati Therapeutics, Inc. (US) | 2022-11-16 | — | — | EP | disclosed |
| WO-2022221528-A2 | KRAS G12C INHIBITORS | Mirati Therapeutics, Inc. (US) | 2022-10-20 | — | — | WO | disclosed |
| US-11339140-B2 | Compositions and methods comprising substituted 2-aminoimidazoles | CURZA GLOBAL, LLC (US) | 2022-05-24 | — | — | US | disclosed |
| US-11324738-B2 | Muscarinic agonists | HEPTARES THERAPEUTICS LIMITED (GB) | 2022-05-10 | — | — | US | disclosed |
| CN-108602818-B | Pyrazole fused ring derivatives, preparation method thereof and application thereof in treating cancer, inflammation and immune diseases | 北京诺诚健华医药科技有限公司 | 2021-12-21 | — | — | CN | disclosed |
| EP-3331528-B1 | MUSCARINIC AGONISTS | HEPTARES THERAPEUTICS LTD (GB) | 2021-09-29 | — | — | EP | disclosed |
| US-20170066743-A1 | SUBSTITUTED AMINO TRIAZOLES USEFUL AS HUMAN CHITINASE INHIBITORS | GALAPAGOS NV (BE) | 2017-03-09 | — | — | US | disclosed |
| WO-2017021728-A1 | MUSCARINIC AGONISTS | HEPTARES THERAPEUTICS LIMTED (GB) | 2017-02-09 | — | — | WO | disclosed |
| EP-2820009-A1 | SERINE/THREONINE KINASE INHIBITORS | Array Biopharma, Inc. (US) | 2015-01-07 | — | — | EP | disclosed |
| WO-2013130976-A1 | SERINE/THREONINE KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2013-09-06 | — | — | WO | disclosed |
| US-8304577-B2 | Modulators of G protein-coupled receptor 88 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-11-06 | — | — | US | disclosed |
| US-20110251196-A1 | Modulators of G Protein-Coupled Receptor 88 | Bristol-Myers Squibb Company and Lexicon Pharmaceuticals, Inc. | 2011-10-13 | — | — | US | disclosed |
| WO-2009032754-A2 | HETEROCYCLODIAZEPINE CANNABINOID RECEPTOR MODULATORS FOR TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2009-03-12 | — | — | WO | disclosed |
| EP-1740556-A1 | HETEROCYCLIC ANTI-VIRAL COMPOUNDS COMPRISING METABOLIZABLE MOIETIES AND THEIR USES | Rigel Pharmaceuticals, Inc. (US) | 2007-01-10 | — | — | EP | disclosed |
| US-20050239751-A1 | Heterocyclic anti-viral compounds comprising metabolizable moieties and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2005-10-27 | — | — | US | disclosed |
| WO-2005097760-A1 | HETEROCYCLIC ANTI-VIRAL COMPOUNDS COMPRISING METABOLIZABLE MOIETIES AND THEIR USES | RIGEL PHARMACEUTICALS, INC. (US) | 2005-10-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110251196-A1 | Modulators of G Protein-Coupled Receptor 88 | GPR88, GPR68, GRK2 | RAB9A 845/4885POLB 4684/4885CPT2 3549/4885 |
| US-11324738-B2 | Muscarinic agonists | CHRM1, CHRM2, CHRM4 | RAB9A 439/4885POLB 3875/4885CPT2 3011/4885 |
| US-11339140-B2 | Compositions and methods comprising substituted 2-aminoimidazoles | AADAC, PAICS, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | RAB9A 2436/4885POLB 1478/4885CPT2 1488/4885 |
| US-20050239751-A1 | Heterocyclic anti-viral compounds comprising metabolizable moieties and their uses | HAVCR2, HCCS, AADAC | RAB9A 2828/4885POLB 834/4885CPT2 1311/4885 |
| US-20170066743-A1 | SUBSTITUTED AMINO TRIAZOLES USEFUL AS HUMAN CHITINASE INHIBITORS | CHIA, CHIT1, AADAC | RAB9A 2453/4885POLB 3468/4885CPT2 4182/4885 |
| US-11834461-B2 | Bicyclic ketone compounds and methods of use thereof | HSD17B7, CYP11B1, CYP11B2 | RAB9A 2444/4885POLB 2158/4885CPT2 358/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.